Antiarrhythmic drugs
How arrhythmias arise, how antiarrhythmic drugs are classified, the pharmacology of the drugs used in emergency care (amiodarone, adenosine, beta blockers, verapamil and diltiazem, digoxin, lignocaine, flecainide, sotalol, magnesium), and their proarrhythmic risks.
By the end of this page you should be able to
- Describe the mechanisms of arrhythmias: abnormal automaticity, triggered activity and re-entry.
- Classify antiarrhythmic drugs and explain use-dependence.
- Describe the pharmacology of amiodarone, adenosine, verapamil, digoxin, flecainide and sotalol.
- Choose a drug for SVT, AF with rapid ventricular response, VT and torsades de pointes.
- Explain why antiarrhythmic drugs can cause arrhythmias.
How arrhythmias arise
- Abnormal automaticity: non-pacemaker cells develop phase 4 depolarisation (ischaemia, hypokalaemia, catecholamines), or the SA node is suppressed.
- Triggered activity: early afterdepolarisations during phase 2 or 3 when repolarisation is prolonged (long QT, torsades de pointes); delayed afterdepolarisations after repolarisation from Ca overload (digoxin toxicity, catecholamines).
- Re-entry: the commonest mechanism. Needs two pathways with different conduction and refractory properties, unidirectional block in one, and slow enough conduction around the circuit that the tissue ahead has recovered. Examples: AVNRT, AVRT (accessory pathway), atrial flutter, scar-related VT. Drugs terminate re-entry by slowing conduction further (to complete block) or prolonging refractoriness.
Classification and use-dependence
The classic scheme groups drugs by their main action: class I Na channel blockers (Ia moderate block and prolonged action potential: procainamide, quinidine; Ib weak, fast on-off, shortened action potential: lignocaine, mexiletine, phenytoin; Ic strong, slow off: flecainide), class II beta blockers, class III K channel blockers that prolong repolarisation (amiodarone, sotalol), and class IV non-dihydropyridine Ca channel blockers (verapamil, diltiazem). Adenosine, digoxin, magnesium and atropine sit outside it. Most drugs fit several classes; a modernised scheme adds pacemaker current blockers (ivabradine) and others.
Use-dependence: Na channel blockers bind open or inactivated channels more than resting ones, so they block more in tissue that fires fast or is depolarised (ischaemic). Lignocaine dissociates quickly, so it barely affects normal tissue at normal rates but blocks ischaemic tissue and tachycardias. Flecainide dissociates slowly and widens the QRS even at normal rates. Class III drugs often show reverse use-dependence: more prolongation at slow rates, which favours torsades during bradycardia.
The drugs
- Amiodarone: blocks K, Na and Ca channels and beta receptors. Huge Vd, half-life of weeks, iodine-rich. Used for VF and pulseless VT refractory to shocks, for VT with a pulse, and for rate or rhythm control in AF in the unwell or those with heart failure. Acute adverse effects: hypotension, bradycardia, phlebitis. Chronic: thyroid, lung, liver, skin, eyes, nerves. Inhibits CYP3A4, CYP2C9 and P-glycoprotein (raises warfarin effect and digoxin levels).
- Adenosine: A1 receptor agonist; opens K(ACh) channels and reduces cAMP in the AV node, producing transient AV block. Half-life under 10 seconds. Terminates re-entry through the AV node (AVNRT, orthodromic AVRT) and reveals flutter waves. Dipyridamole and carbamazepine potentiate it; theophylline antagonises; transplanted hearts are very sensitive. Avoid in pre-excited AF and use caution in severe asthma.
- Beta blockers (class II): reduce phase 4 slope and AV conduction; rate control in AF, SVT prevention, ventricular arrhythmias after infarction, thyrotoxicosis. Esmolol is ultrashort-acting (red cell esterases).
- Verapamil and diltiazem (class IV): block L-type Ca channels in nodal tissue and myocardium; slow AV conduction; terminate AVNRT; rate control in AF. Negative inotropes: avoid in heart failure, with IV beta blockers, in wide-complex tachycardia of uncertain origin (VT collapses) and in pre-excited AF.
- Digoxin: Na/K ATPase inhibition (inotropy) and increased vagal tone (slows AV conduction). Rate control in AF, especially with heart failure; slow onset; ineffective when sympathetic drive is high. Narrow therapeutic index; renally cleared.
- Lignocaine (Ib): an alternative to amiodarone in refractory VF and VT; little effect on atrial tissue.
- Flecainide (Ic): pharmacological cardioversion of recent-onset AF in structurally normal hearts; contraindicated in structural or ischaemic heart disease (increased mortality after infarction). Can convert AF to flutter with 1:1 conduction; often given with an AV nodal blocker.
- Sotalol: beta blockade plus class III action; QT prolongation and torsades, especially in renal impairment and with hypokalaemia.
- Magnesium: first-line for torsades de pointes (suppresses early afterdepolarisations) regardless of the magnesium level; also useful in digoxin toxicity and as an adjunct for AF rate control.
Choosing
- Unstable tachyarrhythmia (shock, ischaemia, syncope, heart failure): synchronised cardioversion, not drugs.
- Regular narrow-complex SVT: vagal manoeuvres (the modified Valsalva with leg raise improves success), then adenosine; verapamil or diltiazem as an alternative.
- AF with rapid ventricular response: treat the cause (sepsis, dehydration, thyrotoxicosis); rate control with a beta blocker or diltiazem, digoxin or amiodarone if the ventricle is poor; cardioversion if onset is clearly within 48 hours or the patient is anticoagulated; anticoagulation decisions follow stroke risk.
- Pre-excited AF (irregular, broad, varying QRS): avoid AV nodal blockers (adenosine, verapamil, diltiazem, digoxin, beta blockers), which push conduction down the accessory pathway; cardioversion or procainamide (flecainide in some practice).
- Monomorphic VT with a pulse: amiodarone (or procainamide) or synchronised cardioversion. Torsades: magnesium, correct potassium, stop QT-prolonging drugs, raise the heart rate (isoprenaline or pacing).
Proarrhythmia
Every antiarrhythmic can cause arrhythmia. Class Ia and III drugs prolong the QT and cause torsades; class Ic drugs slow conduction enough to create re-entrant VT in scarred hearts and organise AF into flutter with fast conduction; class II and IV drugs and digoxin cause bradycardia and AV block; digoxin causes almost any arrhythmia through delayed afterdepolarisations. Electrolyte disturbance, renal impairment, interacting drugs and structural heart disease multiply the risk.
Making the answer flow
- Classify, then pick an emergency drug and give mechanism, kinetics, uses, adverse effects and interactions.
- For a rhythm, say first whether the patient is stable; then the drug and why it suits the mechanism.
- Use the action potential diagram to show where each class acts.
Where marks are lost
- Giving verapamil to a broad-complex tachycardia of uncertain origin.
- Giving AV nodal blockers in pre-excited AF.
- Using flecainide in a patient with ischaemic heart disease.
- Waiting for a low magnesium level before treating torsades.
Where this meets anaesthesia
- Adenosine causes transient atrioventricular block through A1 receptors; its effect lasts seconds, and dipyridamole potentiates it.
- Amiodarone interacts with volatile anaesthetics and beta-blockers to cause bradycardia and hypotension.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
Describe the pharmacology of amiodarone.
Show answer
- Benzofuran derivative, iodinated; class III with I, II, IV actions.
- PK: poor and variable oral bioavailability, very large Vd, highly protein bound, hepatic metabolism to active desethylamiodarone, half-life 40 to 55 days.
- Uses: shock-refractory VF and pVT, VT, AF.
- Adverse: hypotension, bradycardia, phlebitis; thyroid (both directions), pulmonary fibrosis, hepatotoxicity, corneal deposits, photosensitivity, neuropathy, QT prolongation.
- Interactions: warfarin, digoxin, statins, other QT-prolonging drugs.
- 2.
How does adenosine work and what are its limitations?
Show answer
- A1 receptor (Gi): opens K(ACh), reduces cAMP and Ca current in AV node; transient AV block.
- Rapid IV push with flush; half-life under 10 seconds (red cell and endothelial uptake, adenosine deaminase).
- Terminates AVNRT and AVRT; diagnostic in flutter and atrial tachycardia.
- Adverse: flushing, chest pain, dyspnoea, transient asystole, bronchospasm, AF induction.
- Interactions: dipyridamole, carbamazepine (enhance); theophylline, caffeine (reduce); heart transplant (sensitive).
- 3.
Explain re-entry and how drugs terminate it.
Show answer
- Circuit with two limbs, unidirectional block, slow conduction so the wavefront finds recovered tissue.
- Examples: AVNRT, AVRT, flutter, scar VT.
- Termination: slow conduction to the point of block (class I, IV, adenosine at the AV node) or prolong refractory period so the wavefront meets refractory tissue (class III).
- Also cardioversion depolarises the whole circuit at once.
- 4.
A patient has an irregular broad-complex tachycardia at 250 per minute and is alert. What do you worry about and which drugs do you avoid?
Show answer
- Pre-excited AF (WPW): very fast conduction down an accessory pathway; risk of VF.
- Avoid AV nodal blockers: adenosine, verapamil, diltiazem, digoxin, beta blockers (and amiodarone is debated).
- Treatment: synchronised cardioversion if any instability; procainamide where available; expert advice.
- Later ablation of the pathway.
- 5.
What is torsades de pointes and how is it treated?
Show answer
- Polymorphic VT with twisting QRS axis, occurring with a prolonged QT.
- Early afterdepolarisations during prolonged repolarisation trigger it, often after a pause (short-long-short).
- Causes: drugs, hypokalaemia, hypomagnesaemia, congenital long QT, bradycardia.
- Treatment: magnesium IV, correct K, stop drugs, increase heart rate (isoprenaline, overdrive pacing), defibrillate if pulseless.
- 6.
Why is verapamil dangerous in ventricular tachycardia?
Show answer
- Negative inotrope and vasodilator; VT patients often have poor ventricles.
- Does not terminate most VT (not nodal-dependent).
- Causes profound hypotension and collapse.
- Hence: treat a broad-complex tachycardia as VT until proven otherwise.
- 7.
Compare drugs used for rate control in atrial fibrillation.
Show answer
- Beta blockers: first-line, effective during exercise; caution in decompensated heart failure and asthma.
- Diltiazem and verapamil: effective; avoid in heart failure with reduced EF.
- Digoxin: slow onset, vagally mediated (poor control with exertion or high sympathetic tone); useful in heart failure and sedentary patients.
- Amiodarone: in critically ill or heart failure; may cardiovert (consider anticoagulation).
- 8.
Explain use-dependence using lignocaine and flecainide.
Show answer
- Na channel blockers bind open and inactivated channels preferentially.
- Lignocaine: fast binding and unbinding (under a second): little block at normal rates, more at fast rates and in depolarised ischaemic tissue.
- Flecainide: slow unbinding (many seconds): block accumulates even at normal rates; QRS widening.
- Clinical: lignocaine useful in ischaemic VT; flecainide proarrhythmic in structural heart disease.
- 9.
What are the features of digoxin toxicity and how is it treated?
Show answer
- GI (nausea, vomiting), neuro (confusion, visual disturbance: xanthopsia), cardiac (bradyarrhythmias, AV block, atrial tachycardia with block, bidirectional VT, ventricular ectopy).
- Acute: hyperkalaemia (Na/K ATPase block), a marker of severity. Chronic: often hypokalaemia from diuretics, renal impairment, interacting drugs.
- Treatment: digoxin-specific antibody fragments for life-threatening arrhythmia, hyperkalaemia, or large ingestion; correct K and Mg; atropine for bradycardia; avoid cardioversion if possible.
Practise this week
- Investigations Lab: gases, ECGs and lung function
- Primary MCQs: pharmacology
- Primary SAQs, marked part by part
- Primary vivas
- Viva Examiner: practise answering aloud
Week 9 in the other subjects
- Physiology: The cardiac cycle and pressure-volume loops
Not affiliated with the Australian and New Zealand College of Anaesthetists (ANZCA). Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.